search
Back to results

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Sitagliptin phosphate/metformin hydrochloride FDC
Sitagliptin phosphate
Metformin hydrochloride
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • is in good health
  • is a nonsmoker
  • is willing to follow all study guidelines

Exclusion Criteria:

  • has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant
  • is a nursing mother
  • is unwilling to consume the required high-fat breakfast

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Sita + Met then Sita/Met FDC

    Sita/Met FDC then Sita + Met

    Arm Description

    Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.

    Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.

    Outcomes

    Primary Outcome Measures

    Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin
    Serum samples were used to determine the AUC from time 0 to infinity for metformin.

    Secondary Outcome Measures

    Peak Plasma Concentration (Cmax) of Metformin
    Serum samples were used to determine the maximum concentration for metformin.

    Full Information

    First Posted
    June 25, 2009
    Last Updated
    July 22, 2015
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00929201
    Brief Title
    Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
    Official Title
    An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the Final Marketed Image (FMI) Sitagliptin/Metformin Fixed-Dose Combination (FDC) Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2008 (undefined)
    Primary Completion Date
    March 2008 (Actual)
    Study Completion Date
    May 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    61 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sita + Met then Sita/Met FDC
    Arm Type
    Active Comparator
    Arm Description
    Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
    Arm Title
    Sita/Met FDC then Sita + Met
    Arm Type
    Active Comparator
    Arm Description
    Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
    Intervention Type
    Drug
    Intervention Name(s)
    Sitagliptin phosphate/metformin hydrochloride FDC
    Intervention Description
    Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
    Intervention Type
    Drug
    Intervention Name(s)
    Sitagliptin phosphate
    Intervention Description
    Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin hydrochloride
    Intervention Description
    Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
    Primary Outcome Measure Information:
    Title
    Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin
    Description
    Serum samples were used to determine the AUC from time 0 to infinity for metformin.
    Time Frame
    Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose
    Secondary Outcome Measure Information:
    Title
    Peak Plasma Concentration (Cmax) of Metformin
    Description
    Serum samples were used to determine the maximum concentration for metformin.
    Time Frame
    Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: is in good health is a nonsmoker is willing to follow all study guidelines Exclusion Criteria: has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant is a nursing mother is unwilling to consume the required high-fat breakfast
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

    We'll reach out to this number within 24 hrs